The approval of a 1-for-80 reversestocksplit is expected to help the company regain compliance with Nasdaq listing requirements, which is crucial for maintaining its public company status.
Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a biopharmaceutical company with a market capitalization of $83.66 million and currently trading at $0.66 per share, held a Special Meeting of Stockholders ...
Glucotrack’s Common Stock will continue to trade on the Nasdaq Capital Market (“Nasdaq”) under the symbol “GCTK”. The new CUSIP number for the Common Stock following the Reverse Stock Split will be ...
Results that may be inaccessible to you are currently showing.